Presence of S100A9-positive inflammatory cells in cancer tissues correlates with an early stage cancer and a better prognosis in patients with gastric cancer

BMC Cancer

Biao Fan¹  Lian-Hai Zhang¹  Yong-ning Jia¹  Xi-Yao Zhong¹  Yi-Qiang Liu⁶  Xiao-Jing Cheng³  Xiao-Hong Wang³  Xiao-Fang Xing³  Ying Hu²  Ying-Ai Li²  Hong Du²  Wei Zhao⁵  Zhao-Jian Niu⁴  Ai-Ping Lu⁶  Ji-You Li⁶  Jia-Fu Ji¹ 

[1] Department of Surgery, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

[2] Tissue Bank, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

[3] Clinical Gastric Cancer Research Laboratory, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

[4] Department of General Surgery, Affiliated Hospital of Medical College Qingdao University, Shandong Province, China

[5] Clinical Research Laboratory, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

[6] Department of Pathology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

关键词: Survival;    Tumor staging;    Inflammatory cells;    S100A9;    Gastric cancer;   

Others  :  1080291
DOI  :  10.1186/1471-2407-12-316

 received in 2012-04-27, accepted in 2012-07-07,  发布年份 2012

【 摘 要 】

Background

S100A9 was originally discovered as a factor secreted by inflammatory cells. Recently, S100A9 was found to be associated with several human malignancies. The purpose of this study is to investigate S100A9 expression in gastric cancer and explore its role in cancer progression.

Methods

S100A9 expression in gastric tissue samples from 177 gastric cancer patients was assessed by immunohistochemistry. The expression of its dimerization partner S100A8 and the S100A8/A9 heterodimer were also assessed by the same method. The effect of exogenous S100A9 on motility of gastric cancer cells AGS and BGC-823 was then investigated.

Results

S100A9 was specifically expressed by inflammatory cells such as macrophages and neutrophils in human gastric cancer and gastritis tissues. Statistical analysis showed that a high S100A9 cell count (> = 200) per 200x magnification microscopic field in cancer tissues was predictive of early stage gastric cancer. High S100A9-positive cell count was negatively correlated with lymph node metastasis (P = 0.009) and tumor invasion (P = 0.011). S100A9 was identified as an independent prognostic predictor of overall survival of patients with gastric cancer (P = 0.04). Patients with high S100A9 cell count were with favorable prognosis (P = 0.021). Further investigation found that S100A8 distribution in human gastric cancer tissues was similar to S100A9. However, the number of S100A8-positive cells did not positively correlate with patient survival. The inflammatory cells infiltrating cancer were S100A8/A9 negative, while those in gastritis were positive. Furthermore, exogenous S100A9 protein inhibited migration and invasion of gastric cancer cells.

Conclusions

Our results suggested S100A9-positive inflammatory cells in gastric cancer tissues are associated with early stage of gastric cancer and good prognosis.

【 授权许可】

   
2012 Fan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Karpeh MS, Leon L, Klimstra D, Brennan MF: Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000, 232(3):362-371.
• [3]Smith DD, Schwarz RR, Schwarz RE: Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005, 23(28):7114-7124.
• [4]Fatourou E, Ziogas D, Baltogiannis G: Moving from lymph node metastasis in gastric cancer to biological markers. World J Surg 2010, 34(5):1140-1141.
• [5]Roukos DH: Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther 2009, 9(4):389-392.
• [6]Ludwig JA, Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5(11):845-856.
• [7]Salama I, Malone PS, Mihaimeed F, Jones JL: A review of the S100 proteins in cancer. Eur J Surg Oncol 2008, 34(4):357-364.
• [8]Leukert N, Sorg C, Roth J: Molecular basis of the complex formation between the two calcium-binding proteins S100A8 (MRP8) and S100A9 (MRP14). Biol Chem 2005, 386(5):429-434.
• [9]Leukert N, Vogl T, Strupat K, Reichelt R, Sorg C, Roth J: Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. J Mol Biol 2006, 359(4):961-972.
• [10]Halayko AJ, Ghavami S: S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can J Physiol Pharmacol 2009, 87(10):743-755.
• [11]Foell D, Wittkowski H, Roth J: Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009, 58(6):859-868.
• [12]Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, Day AS: Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 2007, 42(11):1321-1331.
• [13]Goebeler M, Roth J, Burwinkel F, Vollmer E, Bocker W, Sorg C: Expression and complex formation of S100-like proteins MRP8 and MRP14 by macrophages during renal allograft rejection. Transplantation 1994, 58(3):355-361.
• [14]Rugtveit J, Brandtzaeg P, Halstensen TS, Fausa O, Scott H: Increased macrophage subset in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut 1994, 35(5):669-674.
• [15]Gebhardt C, Nemeth J, Angel P, Hess J: S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006, 72(11):1622-1631.
• [16]Kawai H, Minamiya Y, Takahashi N: Prognostic impact of S100A9 over expression in non-small cell lung cancer. Tumour Biol 2011, 32(4):641-646.
• [17]Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D: Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 2005, 11(14):5146-5152.
• [18]Cross SS, Hamdy FC, Deloulme JC, Rehman I: Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005, 46(3):256-269.
• [19]Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R: S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 2008, 8(4):243-252.
• [20]Wang J, Cai Y, Xu H, Zhao J, Xu X, Han YL, Xu ZX, Chen BS, Hu H, Wu M, et al.: Expression of MRP14 gene is frequently down-regulated in Chinese human esophageal cancer. Cell Res 2004, 14(1):46-53.
• [21]Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, Jenkins RE, Park BK, Schwarte-Waldhoff I, Khattak I, et al.: Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis 2010, 31(9):1541-1551.
• [22]Yoo BC, Shin YK, Lim SB, Hong SH, Jeong SY, Park JG: Evaluation of calgranulin B in stools from the patients with colorectal cancer. Dis Colon Rectum 2008, 51(11):1703-1709.
• [23]El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, Frierson HF, Powell SM: Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002, 62(23):6823-6826.
• [24]Kim HK, Reyzer ML, Choi IJ, Kim CG, Kim HS, Oshima A, Chertov O, Colantonio S, Fisher RJ, Allen JL, et al.: Gastric cancer-specific protein profile identified using endoscopic biopsy samples via MALDI mass spectrometry. J Proteome Res 2010, 9(8):4123-4130.
• [25]Ji J, Chen X, Leung SY, Chi JT, Chu KM, Yuen ST, Li R, Chan AS, Li J, Dunphy N, et al.: Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. Oncogene 2002, 21(42):6549-6556.
• [26]Zhang YZ, Zhang LH, Gao Y, Li CH, Jia SQ, Liu N, Cheng F, Niu DY, Cho WC, Ji JF, et al.: Discovery and validation of prognostic markers in gastric cancer by genome-wide expression profiling. World J Gastroenterol 2011, 17(13):1710-1717.
• [27]de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6(1):24-37.
• [28]Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010, 140(6):883-899.
• [29]Sheikh AA, Vimalachandran D, Thompson CC, Jenkins RE, Nedjadi T, Shekouh A, Campbell F, Dodson A, Prime W, Crnogorac-Jurcevic T, et al.: The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics 2007, 7(11):1929-1940.
• [30]Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R: S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer 2004, 40(8):1179-1187.
• [31]Foell D, Wittkowski H, Vogl T, Roth J: S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81(1):28-37.
• [32]Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, et al.: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007, 13(9):1042-1049.
• [33]Srikrishna G: S100A8 and S100A9: New Insights into Their Roles in Malignancy. J Innate Immun 2011, 4(1):31-40.
• [34]Ito Y, Arai K, Nozawa R, Yoshida H, Hirokawa M, Fukushima M, Inoue H, Tomoda C, Kihara M, Higashiyama T, et al.: S100A8 and S100A9 expression is a crucial factor for dedifferentiation in thyroid carcinoma. Anticancer Res 2009, 29(10):4157-4161.
• [35]Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L: The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol 2007, 22(9):1025-1032.
• [36]Ghavami S, Chitayat S, Hashemi M, Eshraghi M, Chazin WJ, Halayko AJ, Kerkhoff C: S100A8/A9: a Janus-faced molecule in cancer therapy and tumorgenesis. Eur J Pharmacol 2009, 625(1–3):73-83.
• [37]Yui S, Nakatani Y, Mikami M: Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull 2003, 26(6):753-760.
• [38]Luley K, Noack F, Lehnert H, Homann N: Local calprotectin production in colorectal cancer and polyps–active neutrophil recruitment in carcinogenesis. Int J Colorectal Dis 2011, 26(5):603-607.
• [39]Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117(5):1175-1183.
• [40]Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006, 90:1-50.
• [41]Bui JD, Schreiber RD: Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 2007, 19(2):203-208.
• [42]Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ: Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008, 105(2):652-656.